Used in pharmaceutical research as a key intermediate in the synthesis of kinase inhibitors, particularly targeting TRK (tropomyosin receptor kinase) proteins. It plays a role in the development of small molecule therapies for cancers driven by NTRK gene fusions. Its structure enables selective binding to TRK receptors, making it valuable in creating potent and selective anticancer agents. Also explored in neurodegenerative disease research due to TRK involvement in neuronal signaling.